ClinicalTrials.gg
CompletedNCT00719680Updated Apr 2, 2014Results posted

Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)

A Phase 3 interventional study of IgPro20 in Primary Immune Deficiency, sponsored by CSL Behring. Completed at 4 sites in United States. Open to participants aged 2 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-04-02.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
2 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Primary Immunodeficiency Diseases by CSL Limited — none open to participants now, none under way, none of them phase 3. Primary Immunodeficiency Diseases · CSL Limited.

Enrollment
10th of 13
21 · median 25
Started
2008
with 2 others
Phase 3
9 of 14
none open now
Registered
6th of 14
by date

Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, this one is the 10th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2008, is one of 9 in phase 3, and was the 6th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

None of the 14 studies in Primary Immunodeficiency Diseases by CSL Limited is open now. The open studies under Primary Immunodeficiency Diseases, anywhere →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Primary Immunodeficiency Diseases by CSL Limited as a file.
02

Study summary

The purpose of this study is to determine whether a long-term use of a new human immunoglobulin G with proline (IgPro) is safe and effective in the treatment of primary immunodeficiency.

03

Conditions studied

  • Primary Immune Deficiency

Keywords

  • CVID
  • XLA
04

Who can participate

Ages eligible
2 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with primary humoral immunodeficiency who have participated in the study ZLB04_009CR (NCT00419341), namely with a diagnosis of Common Variable Immunodeficiency (CVID) as defined by PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies) or X-linked Agammaglobulinemia (XLA) as defined by PAGID and ESID
  • Women of must be using and agree to continue using medically approved and must have a negative pregnancy test at screening
  • Written

Exclusion criteria

Exclusion Criteria:

  • Ongoing serious bacterial infection at the time of screening
  • of lymphoid cells such as lymphocytic leukemia, Non-Hodgkin's lymphoma, and immunodeficiency with thymoma
  • Hypoalbuminemia, protein-losing enteropathies, and any proteinuria (defined by total urine protein concentration > 0.2 g/L)
  • Other significant medical conditions that could increase the risk to the patient
  • Females who are pregnant, breast-feeding or planning a pregnancy during the course of the study
  • A positive result at screening on any of the following viral markers: (HIV), virus (HCV) or virus (HBV)
  • (ASAT) or Alanine aminotransferase (ALAT) concentration > 2.5 times Upper Normal Limit (UNL) at Completion Visit of study ZLB04_009CR (NCT00419341)
  • Creatinine concentration > 1.5 times UNL at Completion Visit of study ZLB04_009CR (NCT00419341)
  • Participation in a study with an product other than IgPro20 within 3 months prior to enrollment
  • Evidence of uncooperative attitude
  • Any condition that is likely to interfere with evaluation of the study drug or satisfactory conduct of the trial
  • Subjects who are employees at the investigational site, relatives or spouse of the investigator
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    IgPro20

    The IgPro20 dose will be the same as in the previous pivotal study ZLB04_009CR (NCT00419341) infused subcutaneously weekly or twice a week (in the latter case, half of a weekly dose will be used)

    Biological: IgPro20

Interventions

  • BiologicalIgPro20

    Also known as: IgG with Proline

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Serious Bacterial Infection (Intention-to-Treat Population)

    The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days. Acute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.

    Time frame: For the duration of the study, up to approximately 104 weeks

  2. Annualized Rate of Serious Bacterial Infection (Per-Protocol Efficacy Population)

    The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days. Acute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.

    Time frame: For the duration of the study, up to approximately 104 weeks

Secondary outcomes

  1. Annualized Rate of Any Infection

    The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.

    Time frame: For the duration of the study, up to approximately 104 weeks

  2. Trough Levels of Total Immunoglobulin G (IgG) Serum Concentrations

    Mean of individual median total IgG trough concentration.

    Time frame: Before infusion at Weeks 1, 24, 48, 72, and 96

  3. Number of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection

    Time frame: For the duration of the study, up to approximately 104 weeks

  4. Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection

    The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection, and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.

    Time frame: For the duration of the study, up to approximately 104 weeks

  5. Number of Days of Hospitalization Due to Infection

    Time frame: For the duration of the study, up to approximately 104 weeks

  6. Annualized Rate of Hospitalization Due to Infection

    The annualized rate was based on the total number of days of hospitalization due to infection and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.

    Time frame: For the duration of the study, up to approximately 104 weeks

  7. Use of Antibiotics for Infection Prophylaxis and Treatment

    Annualized rate of days with antibiotics for infection prophylaxis and treatment.

    Time frame: For the duration of the study, up to approximately 104 weeks

  8. Rate of All AEs by Relatedness and Severity

    The rate of AEs was the number of AEs over the number of infusions administered. At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.

    Time frame: For the duration of the study, up to approximately 104 weeks

  9. Relatedness and Severity of All AEs (Percentage of Total AEs)

    At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.

    Time frame: For the duration of the study, up to approximately 104 weeks

  10. Number of Subjects With Any Temporally Associated Adverse Event (AE) Within 24 or 72 Hours After an Infusion

    AEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.

    Time frame: Within 24 or 72 hours after each infusion

  11. Rate of Temporally Associated AEs Within 24 or 72 Hours of an Infusion

    The rate of AEs was the number of AEs over the number of infusions administered. AEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.

    Time frame: Within 24 or 72 hours after each infusion

  12. Number of Subjects Reporting Mild, Moderate, or Severe Local AEs

    In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of infusion site oedema, infusion site reaction, injection site pain, injection site rash, and injection site reaction. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.

    Time frame: For the duration of the study, up to approximately 104 weeks

  13. Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Vital Signs

    Vital signs included blood pressure (systolic and diastolic), heart rate, and body temperature.

    Time frame: At weeks 1, 12, 24, 36, 48, 60, 72, 84, and 96

  14. Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Routine Laboratory Parameters

    Routine laboratory parameters included hematology, blood chemistry, and urinalysis parameters.

    Time frame: At Week 1, and study completion (approximately 104 weeks)

  15. Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Viral Safety Markers

    Viral safety markers included human immunodeficiency virus (HIV)-1, HIV-2, hepatitis A virus (HAV), HBV, HCV, and parvovirus B19.

    Time frame: At Week 1, and study completion (approximately 104 weeks)

07

Results

Posted Jan 25, 2013

Participant flow

Participant flow — Overall Study
MilestoneIgPro20
Started21
Completed16
Not completed5
Withdrew: Adverse event1
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryAnnualized Rate of Serious Bacterial Infection (Intention-to-Treat Population)

The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days. Acute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.

Time frame:
For the duration of the study, up to approximately 104 weeks
Reported as:
Number · infections per subject year
Annualized Rate of Serious Bacterial Infection (Intention-to-Treat Population)
infections per subject yearIgPro20
Annualized Rate of Serious Bacterial Infection (Intention-to-Treat Population)0.06
SecondaryAnnualized Rate of Any Infection

The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.

Time frame:
For the duration of the study, up to approximately 104 weeks
Reported as:
Number · infections per subject year
Annualized Rate of Any Infection
infections per subject yearIgPro20
Annualized Rate of Any Infection2.38
PrimaryAnnualized Rate of Serious Bacterial Infection (Per-Protocol Efficacy Population)

The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days. Acute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.

Time frame:
For the duration of the study, up to approximately 104 weeks
Reported as:
Number · infections per subject year
Annualized Rate of Serious Bacterial Infection (Per-Protocol Efficacy Population)
infections per subject yearIgPro20
Annualized Rate of Serious Bacterial Infection (Per-Protocol Efficacy Population)0.03
SecondaryTrough Levels of Total Immunoglobulin G (IgG) Serum Concentrations

Mean of individual median total IgG trough concentration.

Time frame:
Before infusion at Weeks 1, 24, 48, 72, and 96
Reported as:
Mean · g/L
Trough Levels of Total Immunoglobulin G (IgG) Serum Concentrations
g/LIgPro20
Trough Levels of Total Immunoglobulin G (IgG) Serum Concentrations11.98 ± 3.65
SecondaryNumber of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection
Time frame:
For the duration of the study, up to approximately 104 weeks
Reported as:
Mean · days
Number of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection
daysIgPro20
Number of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection6.67 ± 13.49
SecondaryAnnualized Rate of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection

The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection, and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.

Time frame:
For the duration of the study, up to approximately 104 weeks
Reported as:
Number · days per subject year
Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection
days per subject yearIgPro20
Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection4.28
SecondaryNumber of Days of Hospitalization Due to Infection
Time frame:
For the duration of the study, up to approximately 104 weeks
Reported as:
Mean · days
Number of Days of Hospitalization Due to Infection
daysIgPro20
Number of Days of Hospitalization Due to Infection0.857 ± 2.726
SecondaryAnnualized Rate of Hospitalization Due to Infection

The annualized rate was based on the total number of days of hospitalization due to infection and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.

Time frame:
For the duration of the study, up to approximately 104 weeks
Reported as:
Number · days per subject year
Annualized Rate of Hospitalization Due to Infection
days per subject yearIgPro20
Annualized Rate of Hospitalization Due to Infection0.55
SecondaryUse of Antibiotics for Infection Prophylaxis and Treatment

Annualized rate of days with antibiotics for infection prophylaxis and treatment.

Time frame:
For the duration of the study, up to approximately 104 weeks
Reported as:
Number · days per subject year
Use of Antibiotics for Infection Prophylaxis and Treatment
days per subject yearIgPro20
Use of Antibiotics for Infection Prophylaxis and Treatment83.87 (5 to 673)
SecondaryRate of All AEs by Relatedness and Severity

The rate of AEs was the number of AEs over the number of infusions administered. At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.

Time frame:
For the duration of the study, up to approximately 104 weeks
Reported as:
Number · AEs per infusion
Rate of All AEs by Relatedness and Severity
AEs per infusionIgPro20
All0.661
Unrelated0.137
At least possibly related0.524
Mild0.575
Moderate0.076
Severe0.010
SecondaryRelatedness and Severity of All AEs (Percentage of Total AEs)

At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.

Time frame:
For the duration of the study, up to approximately 104 weeks
Reported as:
Number · percentage of total AEs
Relatedness and Severity of All AEs (Percentage of Total AEs)
percentage of total AEsIgPro20
Unrelated20.7
At least possibly related79.3
Mild87.0
Moderate11.5
Severe1.5
SecondaryNumber of Subjects With Any Temporally Associated Adverse Event (AE) Within 24 or 72 Hours After an Infusion

AEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.

Time frame:
Within 24 or 72 hours after each infusion
Reported as:
Number · participants
Number of Subjects With Any Temporally Associated Adverse Event (AE) Within 24 or 72 Hours After an Infusion
participantsIgPro20
AEs within 24 hours21
AEs within 72 hours21
SecondaryRate of Temporally Associated AEs Within 24 or 72 Hours of an Infusion

The rate of AEs was the number of AEs over the number of infusions administered. AEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.

Time frame:
Within 24 or 72 hours after each infusion
Reported as:
Number · AEs per infusion
Rate of Temporally Associated AEs Within 24 or 72 Hours of an Infusion
AEs per infusionIgPro20
AEs within 24 hours0.322
AEs within 72 hours0.575
SecondaryNumber of Subjects Reporting Mild, Moderate, or Severe Local AEs

In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of infusion site oedema, infusion site reaction, injection site pain, injection site rash, and injection site reaction. Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.

Time frame:
For the duration of the study, up to approximately 104 weeks
Reported as:
Number · participants
Number of Subjects Reporting Mild, Moderate, or Severe Local AEs
participantsIgPro20
Total19
Mild16
Moderate3
Severe0
SecondaryNumber of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Vital Signs

Vital signs included blood pressure (systolic and diastolic), heart rate, and body temperature.

Time frame:
At weeks 1, 12, 24, 36, 48, 60, 72, 84, and 96
Reported as:
Number · participants
Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Vital Signs
participantsIgPro20
Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Vital Signs0
SecondaryNumber of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Routine Laboratory Parameters

Routine laboratory parameters included hematology, blood chemistry, and urinalysis parameters.

Time frame:
At Week 1, and study completion (approximately 104 weeks)
Reported as:
Number · participants
Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Routine Laboratory Parameters
participantsIgPro20
Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Routine Laboratory Parameters0
SecondaryNumber of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Viral Safety Markers

Viral safety markers included human immunodeficiency virus (HIV)-1, HIV-2, hepatitis A virus (HAV), HBV, HCV, and parvovirus B19.

Time frame:
At Week 1, and study completion (approximately 104 weeks)
Reported as:
Number · participants
Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Viral Safety Markers
participantsIgPro20
Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Viral Safety Markers0

Adverse events

Collected over From the time of informed consent until study completion, up to approximately 121 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IgPro20—4/21 (19%)21/21 (100%)
Most frequent serious events
Most frequent serious events
EventIgPro20
CellulitisInfections and infestations1/21
PneumoniaInfections and infestations1/21
Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/21
DiarrheaGastrointestinal disorders1/21
Most frequent other events
Showing 10 of 35
Most frequent other events
EventIgPro20
SinusitisInfections and infestations14/21
Injection site reactionGeneral disorders10/21
Infusion site reactionGeneral disorders9/21
NasopharyngitisInfections and infestations7/21
Oropharyngeal painRespiratory, thoracic and mediastinal disorders6/21
Upper respiratory tract infectionInfections and infestations6/21
ArthralgiaMusculoskeletal and connective tissue disorders5/21
FatigueGeneral disorders5/21
BronchitisInfections and infestations5/21
Influenza-like illnessGeneral disorders4/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)IgPro20
Mean42.4 ± 18.53
Age, Customized
Age, Customized(participants)IgPro20
>= 2 to < 12 years1
>= 12 to < 16 years1
>= 16 to < 65 years16
>= 65 years3
Sex: Female, Male
Sex: Female, Male(Participants)IgPro20
Female15
Male6
08

Study locations

4 sites
  • Contact CSL Behring for facility details
    Centennial, Colorado 80112, United States
  • Contact CSL Behring for facility details
    North Palm Beach, Florida 33408, United States
  • Contact CSL Behring for facility details
    Indianapolis, Indiana 46202, United States
  • Contact CSL Behring for facility details
    Dallas, Texas 75230, United States
09

References and documents

Publications

  • Jolles S, Borte M, Nelson RP Jr, Rojavin M, Bexon M, Lawo JP, Wasserman RL. Long-term efficacy, safety, and tolerability of Hizentra(R) for treatment of primary immunodeficiency disease. Clin Immunol. 2014 Feb;150(2):161-9. doi: 10.1016/j.clim.2013.10.008. Epub 2013 Oct 26. PubMed 24412910 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2008
First posted
Jul 22, 2008
Start
Jun 2008
Primary completionActual
Jun 2010
CompletionActual
Jun 2010
Results first posted
Jan 25, 2013
Last update
Apr 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00719680
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Jul 22, 2008
Start date
Jun 2008
Primary completion
Jun 2010
Completion
Jun 2010
Results posted
Jan 25, 2013
Last update
Apr 2, 2014

Study contacts

Program Director
study director · CSL Behring
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hizentra

Start the discussion